Clinical Data AstraZeneca lung drug gets ‘surprise’ win in COPD trials BioPharma DiveThe treatment, tozorakimab, succeeded where other similar therapies failed and could help a broader group of COPD patients than Dupixent.Clinical DataRespiratoryRead full story pharminent March 27, 2026 (Last updated: March 30, 2026) BioPharma Dive The treatment, tozorakimab, succeeded where other similar therapies failed and could help a broader group of COPD patients than Dupixent. Clinical DataRespiratoryRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Novartis targets Xolair successor in buyout of startup ExcellergyNext: Otsuka picks up PTSD drug with $700M Transcend buy Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
